Linked Life Data

11468151

Source:http://linkedlifedata.com/resource/pubmed/id/11468151

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2001-7-24
pubmed:abstractText
The conditioning regimen prior to stem cell transplantation in 36 patients with high-risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) was intensified by treating patients with a rhenium 188-labeled anti-CD66 monoclonal antibody. Dosimetry was performed prior to therapy, and a favorable dosimetry was observed in all cases. Radioimmunotherapy with the labeled antibody provided a mean of 15.3 Gy of additional radiation to the marrow; the kidney was the normal organ receiving the highest dose of supplemental radiation (mean 7.4 Gy). Radioimmunotherapy was followed by standard full-dose conditioning with total body irradiation (12 Gy) or busulfan and high-dose cyclophosphamide with or without thiotepa. Patients subsequently received a T-cell-depleted allogeneic graft from a HLA-identical family donor (n = 15) or an alternative donor (n = 17). In 4 patients without an allogeneic donor, an unmanipulated autologous graft was used. Infusion-related toxicity due to the labeled antibody was minimal, and no increase in treatment-related mortality due to the radioimmunoconjugate was observed. Day +30 and day +100 mortalities were 3% and 6%, respectively, and after a median follow-up of 18 months treatment-related mortality was 22%. Late renal toxicity was observed in 17% of patients. The relapse rate of 15 patients undergoing transplantation in first CR (complete remission) or second CR was 20%; 21 patients not in remission at the time of transplantation had a 30% relapse rate. (Blood. 2001;98:565-572)
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0006-4971
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
98
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
565-72
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:11468151-Acute Disease, pubmed-meshheading:11468151-Adolescent, pubmed-meshheading:11468151-Adult, pubmed-meshheading:11468151-Antibodies, Monoclonal, pubmed-meshheading:11468151-Antigens, CD, pubmed-meshheading:11468151-Antigens, Differentiation, pubmed-meshheading:11468151-Cell Adhesion Molecules, pubmed-meshheading:11468151-Female, pubmed-meshheading:11468151-Hematopoietic Stem Cell Transplantation, pubmed-meshheading:11468151-Humans, pubmed-meshheading:11468151-Leukemia, Myeloid, pubmed-meshheading:11468151-Lymphocyte Depletion, pubmed-meshheading:11468151-Male, pubmed-meshheading:11468151-Middle Aged, pubmed-meshheading:11468151-Myelodysplastic Syndromes, pubmed-meshheading:11468151-Radioimmunotherapy, pubmed-meshheading:11468151-Radioisotopes, pubmed-meshheading:11468151-Rhenium, pubmed-meshheading:11468151-Risk Factors, pubmed-meshheading:11468151-T-Lymphocytes, pubmed-meshheading:11468151-Transplantation Conditioning, pubmed-meshheading:11468151-Treatment Outcome
pubmed:year
2001
pubmed:articleTitle
Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study.
pubmed:affiliation
Department of Haematology/Oncology, Ulm University Hospital, Robert-Koch-Strasse 8, 89091 Ulm, Germany. donald.bunjes@medizin.uni-ulm.de
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II, Clinical Trial, Phase I